Abstract | INTRODUCTION: PATIENTS AND METHODS: Patients with pT1/T2N0M0 disease whose tumors demonstrated ≥ 10% nuclear reactivity on centrally performed immunohistochemistry for p53 were offered random assignment to three cycles of adjuvant MVAC versus observation; p53-negative patients were observed. By using a log-rank test with one-sided α = .05 and β = .10, 190 p53-positive patients were planned to be randomly assigned to detect an absolute improvement in probability of recurring by 3 years from 0.50 to 0.30. RESULTS: A total of 521 patients were registered, 499 underwent p53 assessment, 272 (55%) were positive, and 114 (42%) were randomly assigned. Accrual was halted on the basis of the data and safety monitoring board review of a futility analysis. Overall 5-year probability of recurring was 0.20 (95% CI, 0.16 to 0.24) with no difference on the basis of p53 status. Only 67% of patients randomly assigned to MVAC received all three cycles with 12 patients receiving no treatment. There was no difference in recurrence in the randomly assigned patients (hazard ratio, 0.78; 95% CI, 0.29 to 2.08; P = .62). CONCLUSION: Neither the prognostic value of p53 nor the benefit of MVAC chemotherapy in patients with p53-positive tumors was confirmed, but the high patient refusal rate, lower than expected event rate, and failures to receive assigned therapy severely compromised study power.
|
Authors | Walter M Stadler, Seth P Lerner, Susan Groshen, John P Stein, Shan-Rong Shi, Derek Raghavan, David Esrig, Gary Steinberg, David Wood, Laurence Klotz, Craig Hall, Donald G Skinner, Richard J Cote |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 29
Issue 25
Pg. 3443-9
(Sep 01 2011)
ISSN: 1527-7755 [Electronic] United States |
PMID | 21810677
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Chemical References |
- TP53 protein, human
- Tumor Suppressor Protein p53
- Vinblastine
- Doxorubicin
- Cisplatin
- Methotrexate
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma in Situ
(drug therapy, genetics)
- Carcinoma, Transitional Cell
(drug therapy, metabolism)
- Cisplatin
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Immunoenzyme Techniques
- Male
- Methotrexate
(administration & dosage)
- Molecular Targeted Therapy
- Prospective Studies
- Survival Rate
- Treatment Outcome
- Tumor Suppressor Protein p53
(metabolism)
- Urinary Bladder Neoplasms
(drug therapy, metabolism)
- Vinblastine
(administration & dosage)
|